Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts

Despite efforts to discover effective treatments to eradicate tuberculosis (TB), it remains a global threat. The increase in drug-resistant bacterial species has made the discovery of new drugs highly coveted. The utilisation of previous efficacious structures is one approach that can be employed to...

Full description

Saved in:
Bibliographic Details
Main Authors: Yucheng Lu, Daniel Partleton, Filibus M. Gugu, Ahmed Y. G. Alhejaili, Samuel Norris, J. Jonathan Harburn, Jason H. Gill, Jonathan D. Sellars, Alistair K. Brown
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2025.2502600
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849732046162755584
author Yucheng Lu
Daniel Partleton
Filibus M. Gugu
Ahmed Y. G. Alhejaili
Samuel Norris
J. Jonathan Harburn
Jason H. Gill
Jonathan D. Sellars
Alistair K. Brown
author_facet Yucheng Lu
Daniel Partleton
Filibus M. Gugu
Ahmed Y. G. Alhejaili
Samuel Norris
J. Jonathan Harburn
Jason H. Gill
Jonathan D. Sellars
Alistair K. Brown
author_sort Yucheng Lu
collection DOAJ
description Despite efforts to discover effective treatments to eradicate tuberculosis (TB), it remains a global threat. The increase in drug-resistant bacterial species has made the discovery of new drugs highly coveted. The utilisation of previous efficacious structures is one approach that can be employed to developing novel series of compounds to combat this ever-growing problem. This study sought to re-examine two such compounds, isoxyl (ISO) and SQ109, previously shown to be efficacious in TB treatment. SQ109-ISO hybrid compounds were shown to have demonstrable activity against both drug-sensitive and drug-resistant Mtb whilst displaying limited toxicity in vitro in comparison to other antitubercular agents. Indications from our genetic and biochemical studies suggest that these structurally similar pharmacophores bind to different proteins within Mtb, highlighting the need for careful consideration when producing regioisomeric analogues and that the utilisation of previous efficacious structures is a valid approach to developing promising novel drugs against Mtb.
format Article
id doaj-art-e86ebb26f44b46fd8a6a81c411ff1015
institution DOAJ
issn 1475-6366
1475-6374
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Journal of Enzyme Inhibition and Medicinal Chemistry
spelling doaj-art-e86ebb26f44b46fd8a6a81c411ff10152025-08-20T03:08:21ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742025-12-0140110.1080/14756366.2025.2502600Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adductsYucheng Lu0Daniel Partleton1Filibus M. Gugu2Ahmed Y. G. Alhejaili3Samuel Norris4J. Jonathan Harburn5Jason H. Gill6Jonathan D. Sellars7Alistair K. Brown8Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UKBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UKBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UKBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UKChemistry, School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, UKSchool of Pharmacy, Faculty of Medical Sciences, King George VI Building, Newcastle upon Tyne, UKSchool of Pharmacy, Faculty of Medical Sciences, King George VI Building, Newcastle upon Tyne, UKBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UKBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UKDespite efforts to discover effective treatments to eradicate tuberculosis (TB), it remains a global threat. The increase in drug-resistant bacterial species has made the discovery of new drugs highly coveted. The utilisation of previous efficacious structures is one approach that can be employed to developing novel series of compounds to combat this ever-growing problem. This study sought to re-examine two such compounds, isoxyl (ISO) and SQ109, previously shown to be efficacious in TB treatment. SQ109-ISO hybrid compounds were shown to have demonstrable activity against both drug-sensitive and drug-resistant Mtb whilst displaying limited toxicity in vitro in comparison to other antitubercular agents. Indications from our genetic and biochemical studies suggest that these structurally similar pharmacophores bind to different proteins within Mtb, highlighting the need for careful consideration when producing regioisomeric analogues and that the utilisation of previous efficacious structures is a valid approach to developing promising novel drugs against Mtb.https://www.tandfonline.com/doi/10.1080/14756366.2025.2502600MycobacteriumadamantylisoxylSQ109antitubercular
spellingShingle Yucheng Lu
Daniel Partleton
Filibus M. Gugu
Ahmed Y. G. Alhejaili
Samuel Norris
J. Jonathan Harburn
Jason H. Gill
Jonathan D. Sellars
Alistair K. Brown
Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts
Journal of Enzyme Inhibition and Medicinal Chemistry
Mycobacterium
adamantyl
isoxyl
SQ109
antitubercular
title Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts
title_full Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts
title_fullStr Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts
title_full_unstemmed Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts
title_short Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts
title_sort structural isomerisation affects the antitubercular activity of adamantyl isoxyl adducts
topic Mycobacterium
adamantyl
isoxyl
SQ109
antitubercular
url https://www.tandfonline.com/doi/10.1080/14756366.2025.2502600
work_keys_str_mv AT yuchenglu structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT danielpartleton structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT filibusmgugu structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT ahmedygalhejaili structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT samuelnorris structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT jjonathanharburn structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT jasonhgill structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT jonathandsellars structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts
AT alistairkbrown structuralisomerisationaffectstheantitubercularactivityofadamantylisoxyladducts